Evaluation of monoclonal antibody MIB‐1 in the mammary epithelium adjacent to fibroadenomas in premenopausal women treated with tamoxifen

Sousa, Juarez Antônio de; Seixas, Maria Teresa; Lima, Geraldo Rodrigues de; Baracat, E.C.; Gebrim, LH

doi:10.1016/s0020-7292(00)82771-x

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…De Sousa et al [13] confirmed that tamoxifen significantly reduced Ki-67 expression in the non-neoplastic breast epithelium of premenopausal women. De Lima et al [8] showed that at doses of 5, 10, and 20 mg/day, tamoxifen significantly reduced the positivity of estrogen and progesterone receptors in the non-neoplastic breast epithelium of premenopausal women, while more recently, Da Silva et al [14] showed a reduction in cell proliferation in the nonneoplastic breast following Ki-67 protein evaluation in premenopausal women exposed to raloxifene.…”

Section: Discussionmentioning

confidence: 88%

Evaluation of estrogen and progesterone receptors in non-neoplastic breast tissue of women of reproductive age exposed to tamoxifen and raloxifene: a randomized, double-blind study

Rosal

Silva

2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

The objective of the present study was to compare the effects of tamoxifen and raloxifene in non-neoplastic breast epithelium. A randomized, double-blind study was carried out in 57 ovulatory, premenopausal women of 18-40 years of age, who had been diagnosed with fibroadenoma of the breast. The patients were divided into three groups: Group A: placebo, n=20; Group B: tamoxifen 20 mg/day, n = 21; and Group C: raloxifene 60mg/day, n=16. The study medication was given for 22 days starting on the first day of the menstrual cycle. On the 23rd day, the fibroadenoma was removed and a sample of non-neoplastic breast tissue was collected for immunohistochemical evaluation of estrogen and progesterone receptors. Comparison between the mean percentages of stained nuclei in the three groups was performed by analysis of variance and multiple comparisons, using Tukey's method to compare pairwise means, with significance established at P < 0.05. Exposition to tamoxifen or raloxifene resulted in a significant and similar reduction in the mean percentage of stained nuclei for estrogen and progesterone receptors (P<0.0001). Tamoxifen and raloxifene reduce progesterone and estrogen receptor alpha expression significantly and to a similar extent in the non-neoplastic breast tissue of women of reproductive age.

show abstract

Section: Discussionmentioning

confidence: 88%

Evaluation of estrogen and progesterone receptors in non-neoplastic breast tissue of women of reproductive age exposed to tamoxifen and raloxifene: a randomized, double-blind study

Rosal

Silva

2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…In experimental studies, the drug has been shown to significantly reduce the proliferative activity of normal human breast tissue [15,16,18,19]. Nevertheless, when tamoxifen is used for long periods of time, the incidence of endometrial carcinoma is increased 3-4-fold in postmenopausal patients [1], and this concern has increased interest in studying other SERMS that may have a lesser impact or no effect on the endometrium and may have the same or greater efficacy in the chemoprevention of breast cancer in high risk women.…”

Section: Discussionmentioning

confidence: 99%

Effects of raloxifene on normal breast tissue from premenopausal women

Silva

Lopes

Gebrim

2005

Breast Cancer Res Treat

View full text Add to dashboard Cite

The objective of this study was to evaluate the effects of raloxifene on normal breast tissue. A randomized, double-blind study was carried out in 30 ovulatory, premenopausal women of 18-40 years of age, who had been diagnosed with fibroadenoma of the breast. The patients were divided into two groups: Group A (placebo, n = 16) and Group B (raloxifene 60 mg, n = 14). The medication was given for 22 days, beginning on the first day of the menstrual cycle. An excisional biopsy was carried out on the 23rd day during which a sample of normal breast tissue was collected to evaluate the presence of the proliferating cell marker Ki-67. Student's t-test was used for the statistical analysis of data (p < 0.05). Mean percentage of stained nuclei in groups A and B was 10.96 +/- 1.27 and 1.21 +/- 0.26, respectively (p < 0.001). Raloxifene significantly reduced the proliferative activity of normal breast tissue in premenopausal women.

show abstract

Evaluation of monoclonal antibody MIB‐1 in the mammary epithelium adjacent to fibroadenomas in premenopausal women treated with tamoxifen

Cited by 2 publications

References 0 publications

Evaluation of estrogen and progesterone receptors in non-neoplastic breast tissue of women of reproductive age exposed to tamoxifen and raloxifene: a randomized, double-blind study

Evaluation of estrogen and progesterone receptors in non-neoplastic breast tissue of women of reproductive age exposed to tamoxifen and raloxifene: a randomized, double-blind study

Effects of raloxifene on normal breast tissue from premenopausal women

Contact Info

Product

Resources

About